Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RNBLS
ADC Name
chAb2-CZ
Synonyms
chAb2 CZ; chAb2CZ
   Click to Show/Hide
Organization
AbbVie, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast ductal carcinoma [ICD11:2C61]
Investigative
Drug-to-Antibody Ratio
1
Antibody Name
chAb2 (chimra IgG1)
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
chAb2-CZ linker
Combination Type
AbbVie's CZ
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
4.77
nM
HCC38 cells
Breast ductal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 4.77 nM Positive CD276 expression (CD276 +++/++)
Method Description
Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model Breast ductal carcinoma HCC38 cells CVCL_1267
References
Ref 1 Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.